Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

SynAct Pharma

20,55 SEK

+0,49 %

Mindre end 1K følgere

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+0,49 %
-10,26 %
+8,04 %
+9,78 %
+129,22 %
+82,55 %
-67,60 %
-41,31 %
+345,81 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Læs mere
Markedsværdi
1,1 mia. SEK
Aktieomsætning
859,91 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
18.2
2026

Årsrapport '25

Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Selskabsmeddelelse27.11.2025, 10.15

Report from the Extraordinary General Meeting of SynAct Pharma AB

SynAct Pharma
Pressemeddelelse19.11.2025, 07.34

BioStock: Video from SynAct Pharma's presentation at BioStock Life Science Summit 2025

SynAct Pharma
Pressemeddelelse19.11.2025, 06.30

SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th

SynAct Pharma

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser6.11.2025, 09.37

Synact Pharma: Differentiated inflammation resolution approach - Edison

SynAct Pharma is focused on inflammation resolution therapeutics. Its lead asset, resomelagon, is differentiated by its novel mechanism, targeting specific melanocortin receptor subtypes believed to have direct effects on the immune system. The main ...

SynAct Pharma
Pressemeddelelse3.11.2025, 07.00

Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion

SynAct Pharma
Pressemeddelelse31.10.2025, 10.44

Redeye: SynAct (Q3 Update) - ADVANCE Approaching Full Recruitment

SynAct Pharma
Pressemeddelelse31.10.2025, 10.43

BioStock: SynAct advances pipeline and extends runway to 2027

SynAct Pharma
Pressemeddelelse31.10.2025, 07.00

SynAct Pharma Participating in Partnering and Investor Conference Bio-Europe® 2025

SynAct Pharma
Selskabsmeddelelse30.10.2025, 06.30

SynAct Pharma publishes Q3 2025 interim results

SynAct Pharma
Selskabsmeddelelse29.10.2025, 17.30

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SYNACT PHARMA AB

SynAct Pharma
Pressemeddelelse28.10.2025, 09.50

Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma

SynAct Pharma
Pressemeddelelse10.10.2025, 11.00

BioStock: SynAct Pharma's CBO: “We are pioneering the future of inflammation care”

SynAct Pharma
Pressemeddelelse8.10.2025, 06.05

BioStock: SynAct Pharma: "We're on track and on time"

SynAct Pharma
Selskabsmeddelelse29.9.2025, 05.45

Proposal for a resolution on authorization for the Board of Directors to resolve on acquisition and transfer of own shares

SynAct Pharma
Pressemeddelelse25.9.2025, 05.30

SynAct Pharma to Participate in Nordic Life Science Days 2025

SynAct Pharma
Selskabsmeddelelse16.9.2025, 06.45

SynAct Pharma’s CFO Björn Westberg leaves for new leading position

SynAct Pharma
Pressemeddelelse8.9.2025, 05.00

SynAct Pharma AB - Notification of Warrant and Share Transactions by Hunter Capital AB and Heights Capital Management

SynAct Pharma
Pressemeddelelse5.9.2025, 05.50

SynAct appoints Mads Bjerregaard as Chief Business Officer

SynAct Pharma
Selskabsmeddelelse29.8.2025, 16.00

Change in number of shares and votes in SynAct Pharma AB

SynAct Pharma
Pressemeddelelse21.8.2025, 15.10

BioStock: SynAct Pharma strengthens strategy and financials in Q2

SynAct Pharma
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.